Edition:
United States

Ovid Therapeutics Inc (OVID.OQ)

OVID.OQ on NASDAQ Stock Exchange Global Select Market

10.14USD
19 Apr 2018
Change (% chg)

$0.42 (+4.32%)
Prev Close
$9.72
Open
$9.70
Day's High
$10.18
Day's Low
$9.70
Volume
8,824
Avg. Vol
28,621
52-wk High
$15.70
52-wk Low
$5.28

Select another date:

Thu, Mar 29 2018

BRIEF-Ovid Therapeutics Reports Q4 Loss Per Share $0.45

* OVID THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND CORPORATE PROGRESS

BRIEF-Ovid Therapeutics Announces OV101 Granted Fast Track Designation By FDA For Fragile X Syndrome Treatment

* OVID THERAPEUTICS ANNOUNCES OV101 GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF FRAGILE X SYNDROME

BRIEF-Ovid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation By U.S. FDA For Treatment Of Lennox-Gastaut Syndrome

* OVID THERAPEUTICS ANNOUNCES TAK-935/OV935 GRANTED ORPHAN DRUG DESIGNATION BY U.S. FDA FOR TREATMENT OF LENNOX-GASTAUT SYNDROME

BRIEF-Ovid Therapeutics Announces OV101 Granted Fast Track Designation By U.S. FDA For Treatment Of Angelman Syndrome

* OVID THERAPEUTICS ANNOUNCES OV101 GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF ANGELMAN SYNDROME

BRIEF-Ovid Therapeutics Announces TAK-935/Ov935 Has Received Orphan Drug Designation From U.S. FDA For Treatment Of Dravet Syndrome

* OVID THERAPEUTICS ANNOUNCES TAK-935/OV935 HAS RECEIVED ORPHAN DRUG DESIGNATION FROM U.S. FDA FOR TREATMENT OF DRAVET SYNDROME

BRIEF-Ovid Therapeutics Announces OV101 Shows Comparable Pk Profile In Phase 1 Study Of Adolescent Patients

* OVID THERAPEUTICS ANNOUNCES OV101 SHOWS COMPARABLE PK PROFILE IN PHASE 1 STUDY OF ADOLESCENT PATIENTS AND AMENDS PHASE 2 STARS CLINICAL TRIAL PROTOCOL TO INCLUDE ADOLESCENTS

BRIEF-Ovid Therapeutics Q3 loss per share $0.38

* Ovid Therapeutics reports third quarter 2017 financial results and corporate progress

Select another date: